Shattuck Labs, Inc. (STTK) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.29
↑+238% vs avg
5yr avg: 1.56
30Y Low0.6·High7.1
ROE
↓
-60.3%
↑-24% vs avg
5yr avg: -48.6%
30Y Low-67%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
STTK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Shattuck Labs, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $300M | $254M | $61M | $304M | $97M | $358M | $2.2B | — | — |
| Enterprise Value | $247M | $201M | $7M | $182M | $55M | $265M | $2.0B | — | — |
| P/E Ratio → | -8.94 | — | — | — | — | — | — | — | — |
| P/S Ratio | 299.87 | 253.99 | 10.74 | 183.31 | 149.50 | 11.92 | 220.36 | — | — |
| P/B Ratio | 5.29 | 3.08 | 0.77 | 2.10 | 0.55 | 1.32 | 7.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
STTK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 201.38 | 1.30 | 110.03 | 84.35 | 8.84 | 204.46 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
STTK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Shattuck Labs, Inc. earns an operating margin of -5150.8%. Operating margins have expanded from -5549.6% to -5150.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -60.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -268.8% | -268.8% | 100.0% | -143.9% | 100.0% | 95.4% | -277.3% | -195.5% | -10.5% |
| Operating Margin | -5150.8% | -5150.8% | -1408.3% | -5549.6% | -15848.0% | -150.8% | -371.8% | -253.5% | -27.4% |
| Net Profit Margin | -4880.9% | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% | -242.6% | -32.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | -60.3% | -67.2% | -54.4% | -45.5% | -15.5% | -26.6% | — | — |
| ROA | -53.6% | -53.6% | -60.2% | -47.8% | -40.5% | -13.9% | -18.6% | -42.4% | -10.8% |
| ROIC | -139.4% | -139.4% | -247.0% | -87.9% | -49.5% | -20.5% | -50.2% | — | — |
| ROCE | -62.0% | -62.0% | -70.0% | -56.0% | -45.5% | -14.9% | -20.7% | -69.3% | -13.0% |
STTK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $54M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.04 | 0.03 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.64 | -0.68 | -0.84 | -0.24 | -0.34 | -0.51 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -1.81 |
Net cash position: cash ($54M) exceeds total debt ($2M)
STTK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Shattuck Labs, Inc.'s current ratio of 11.70x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.51x to 11.70x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.70 | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 | 2.12 | 3.15 |
| Quick Ratio | 11.70 | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 | 2.12 | 3.15 |
| Cash Ratio | 11.07 | 11.07 | 8.19 | 11.41 | 6.46 | 10.93 | 19.93 | 1.96 | 2.90 |
| Asset Turnover | — | 0.01 | 0.06 | 0.01 | 0.00 | 0.10 | 0.03 | 0.22 | 0.33 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
STTK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Shattuck Labs, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $70M | $51M | $43M | $42M | $42M | $42M | $42M | $15M |
Peer Comparison
Compare STTK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 STTKYou | $300M | -8.9 | — | — | -268.8% | -5150.8% | -60.3% | -139.4% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 NKTX | $223M | -2.0 | — | — | — | — | -31.9% | -24.3% | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See STTK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STTK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STTK vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonSTTK — Frequently Asked Questions
Quick answers to the most common questions about buying STTK stock.
What is Shattuck Labs, Inc.'s P/E ratio?
Shattuck Labs, Inc.'s current P/E ratio is -8.9x. This places it at the 50th percentile of its historical range.
What is Shattuck Labs, Inc.'s ROE?
Shattuck Labs, Inc.'s return on equity (ROE) is -60.3%. The historical average is -44.9%.
Is STTK stock overvalued?
Based on historical data, Shattuck Labs, Inc. is trading at a P/E of -8.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Shattuck Labs, Inc.'s profit margins?
Shattuck Labs, Inc. has -268.8% gross margin and -5150.8% operating margin.